AfricaRegulatory
African Pharmaceutical Regulatory Intelligence
EXEMESTANE
14 registrations across 6 African markets— 10 active
Markets with EXEMESTANE
Recent registrations
| Brand / Product | Market | Holder | Status | Expires |
|---|---|---|---|---|
| EXEMEX 25 TABLET, COATED; ORAL | 🇿🇼Zimbabwe | INNOVATA PHARMACEUTICALS | active | Aug 2028 |
| EQUISIN TABLET, COATED; ORAL | 🇿🇼Zimbabwe | EQUITY PHARMACEUTICALS (PTY) LTD | active | Dec 2027 |
| EXEDRAL TABLET, COATED; ORAL | 🇿🇼Zimbabwe | REMEDICA LTD | active | Dec 2027 |
| Aromasin Tablets 25 mg** Tablet | 🇳🇬Nigeria | Pfizer Specialties Ltd | active | Nov 2025 |
| EXMA | 🇿🇦South Africa | Pharmaplan (Pty) Ltd | suspended | Dec 2023 |
| EXEMESTANE ACCORD Comprimé pelliculé / 25 mg | 🇹🇳Tunisia | ACCORD HEALTHCARE LTD | expired | May 2017 |
| AROMAPLEX Comprimé pelliculé / 25 mg | 🇹🇳Tunisia | GENEPHARM S.A | expired | Sept 2016 |
| AROMASINE Comprime enrobé / 25 mg | 🇹🇳Tunisia | PFIZER HOLDING FRANCE | expired | Feb 2006 |
| EQUISIN | 🇿🇦South Africa | Equity Pharmaceutical (Pty) Ltd | active | Jan 1900 |
| EXEMESTANE 25 mg ACTIVO | 🇿🇦South Africa | Activo Health (Pty) Ltd | active | Jan 1900 |
| EXICAN | 🇿🇦South Africa | Ranbaxy (SA) (Pty) Ltd | active | Jan 1900 |
| AROMASIN 25 mg | 🇿🇦South Africa | Pfizer Laboratories (Pty) Ltd | active | Jan 1900 |
| AROMASINE COMPRIME ENROBE | 🇲🇦Morocco | — | active | — |
| AROMASINE 25MG COMPRIME BOITE DE 30 | 🇨🇮Côte d'Ivoire | PFIZER SPECIALTIES LIMITED | active | — |
EXEMESTANE in Africa — Regulatory Overview
EXEMESTANE is registered across 6 African markets with 14 total product registrations on file. Data is sourced directly from official national drug regulatory authorities including South Africa, Tunisia, Zimbabwe, Côte d'Ivoire and 2 more. AfricaRegulatory refreshes this data daily from official government sources.
Of the 14 registrations, 10 (71%) are currently active. Regulatory affairs teams use AfricaRegulatory to track registration expiry dates, identify market incumbents, and monitor approval status across African markets without manual monitoring of each national regulator.